Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Profitability
This table compares Nexentis Technologies and CASI Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexentis Technologies | N/A | -304.79% | -178.91% |
| CASI Pharmaceuticals | -183.93% | N/A | -131.54% |
Institutional & Insider Ownership
61.2% of Nexentis Technologies shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 6.5% of Nexentis Technologies shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Nexentis Technologies has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Nexentis Technologies and CASI Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexentis Technologies | 1 | 0 | 0 | 0 | 1.00 |
| CASI Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares Nexentis Technologies and CASI Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexentis Technologies | $210,000.00 | 3.55 | -$4.00 million | ($96.07) | -0.01 |
| CASI Pharmaceuticals | $26.85 million | 0.10 | -$39.26 million | ($3.01) | -0.07 |
Nexentis Technologies has higher earnings, but lower revenue than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Nexentis Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Nexentis Technologies beats CASI Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Nexentis Technologies
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Receive News & Ratings for Nexentis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexentis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
